Compare CBFV & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBFV | CMPX |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.9M | 154.9M |
| IPO Year | 2014 | 2020 |
| Metric | CBFV | CMPX |
|---|---|---|
| Price | $37.44 | $0.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $42.00 | $5.45 |
| AVG Volume (30 Days) | 2.4K | ★ 4.7M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $43,557,000.00 | N/A |
| Revenue This Year | $15.58 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $24.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.72 | $0.78 |
| 52 Week High | $38.86 | $6.88 |
| Indicator | CBFV | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 21.21 |
| Support Level | $36.88 | N/A |
| Resistance Level | $38.86 | $2.02 |
| Average True Range (ATR) | 0.39 | 0.06 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 99.28 | 1.71 |
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.